FDA’s review of abortion pill to extend into 2027
The Food and Drug Administration (FDA) has announced that its ongoing safety review of the nation’s main abortion pill, mifepristone, will continue into next year, a timeline that was quickly condemned by abortion opponents hoping to see the drug’s use curtailed, reports BritPanorama.
In a court-ordered update provided late Wednesday, the FDA detailed its progress, marking the first substantive information available about the controversial reevaluation ordered by Health Secretary Robert F. Kennedy Jr.
First approved in 2000, mifepristone’s safety and effectiveness have been reaffirmed by the agency multiple times, which also eased several restrictions, including eliminating the requirement for in-person dispensing.
Since President Donald Trump resumed office, anti-abortion groups along with congressional allies have urged a reassessment of the pill to restrict its use further.
The FDA indicated that it anticipates concluding a safety study of the pill by mid-December 2025. A report on its findings is expected “no later than March 2027,” after which the agency will decide on any new restrictions or alterations regarding the drug’s use.
Gavin Oxley from Americans United for Life criticized the decision, describing it as a failure of “true leadership” from Trump administration officials.
“The administration continues to find itself on the wrong side of women’s health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill,” Oxley added.
Mifepristone, in conjunction with a second drug, misoprostol, constitutes the most prevalent method of abortion in the United States.
This FDA update was mandated by a federal judge in a lawsuit from Louisiana, claiming that mail-delivery of mifepristone infringes on the state’s abortion ban. This case is one of several ongoing lawsuits concerning mifepristone.
Last month, a three-judge panel for the 5th U.S. Circuit Court of Appeals scrutinized Louisiana’s case, questioning whether the state has the legal standing to challenge the FDA’s oversight of mifepristone.
A potential ruling from the 5th Circuit regarding the Louisiana situation is unlikely to cause immediate changes, given that the Supreme Court has temporarily blocked any alterations to the drug’s status until it reviews the case again.
The FDA reported that it is employing a “statistical data mining method” to uncover any “unknown safety concerns” that may be associated with the drug, utilizing data gathered from major health networks and insurers.
Alongside the safety study, the agency is also considering several petitions that propose modifications to the prescription and distribution of mifepristone.
Opponents of abortion have concentrated their efforts on a 2021 decision that permitted online prescriptions of the drug and its mailing during the COVID-19 pandemic. This decision was made permanent by President Joe Biden in 2023, undermining numerous state abortion bans, as women can now receive the drug through the mail.
The implications of these ongoing reviews and decisions will extend beyond immediate policy changes, reflecting broader tensions in the national debate over reproductive rights.
